Natera (NTRA)
Applies personalized molecular testing across reproductive health, oncology, and organ health.
Something off on this page? Send us feedback.
Offers molecular tests for women's health, oncology, and organ health through a shared assay and bioinformatics platform. Panorama and Horizon remain the reproductive-health base, Signatera supplies personalized residual-disease testing, and commercialization depends on clinical validation, accredited laboratories, physician adoption, payer coverage, and intellectual-property protection.
Provides molecular testing across women's health, oncology, and organ health using shared assay and bioinformatics capabilities. Panorama and Horizon anchor reproductive screening, while Signatera delivers personalized, tumor-informed residual-disease testing; Prospera and kidney genetics extend the platform into transplant and chronic kidney care.
Execution centers on clinical validation, accredited laboratory operations, physician adoption, and payer coverage. The reproductive-health base remains material as oncology expands, and the Foresight Diagnostics acquisition adds phased-variant technology and a lymphoma entry to the Signatera platform. A global workforce supports these operations.
Revenue remains concentrated in Panorama, Horizon, and Signatera. Laboratory-developed tests, reimbursement and collection, regulatory compliance, and intellectual-property disputes shape how the portfolio is commercialized.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Sep 9, 2026 | UBS | Reiterate | Rating: —Target: $260 | Target: $435 |
| Sep 8, 2026 | Redburn Partners | Target | Target: — | Target: $385 |
| Sep 8, 2026 | RBC Capital | Upgrade | ||
| Aug 12, 2026 | Stephens | Reiterate | Rating: —Target: $54 | Target: $350 |
| Aug 12, 2026 | Guggenheim | Reiterate | Rating: —Target: $290 | Target: $360 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.09B · Total debt $238.5M · Total assets $2.66B · Shareholders' equity $1.82B
- Revenue
- $752.8M
- Operating income
- −$75.8M
- Net income
- −$67.0M
No dividends on record.
| Institutions | 95.62% | 137.83M shares | |
|---|---|---|---|
| 884 holders · as of Jun 30, 2026 | |||
| Insiders | 2.16% | 3.12M shares | |
| 17 holders · as of Sep 18, 2026 | |||
| Other | 2.22% | 3.20M shares | |
| remainder | |||
144.14M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
JPMorgan Chase & CoInstitution | 8.93% | 12.87M | as of Jun 30, 2026 |
BlackRock, Inc.Institution | 7.57% | 10.91M | as of Jun 30, 2026 |
Price T Rowe Associates Inc /MD/Institution | 6.26% | 9.02M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.32% | 6.23M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 4.01% | 5.78M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 16, 2026 | Jonathan Sheena | director, other: CO-FOUNDER | −3,150 | $354.19 |
| Sep 15, 2026 | Jonathan Sheena | director, other: CO-FOUNDER | −6,000 | $350.07 |
| Sep 15, 2026 | Matthew Rabinowitz | director, officer: EXECUTIVE CHAIRMAN | −52,000 | $347.29 |
| Sep 14, 2026 | Matthew Rabinowitz | director, officer: EXECUTIVE CHAIRMAN | −50,000 | $334.76 |
| Sep 11, 2026 | Matthew Rabinowitz | director, officer: EXECUTIVE CHAIRMAN | −50,000 | $327.97 |
- Myriad Genetics
Direct prenatal and carrier-screening rival with hereditary-cancer overlap
- Labcorp
Broad prenatal, carrier-screening, and oncology MRD overlap
- Guardant Health
Leading liquid-biopsy rival across MRD and genomic profiling
- CareDx
Primary transplant-surveillance rival across kidney, heart, and lung
- Quest Diagnostics
Scale competitor in prenatal, carrier screening, and oncology MRD
- Tempus AI
Oncology diagnostics rival across tumor-naive and tumor-informed MRD
- Abbott
Oncology MRD overlap through the acquired Exact Sciences business
- NeoGenomics
Tumor-informed MRD rival with a newly launched solid-tumor assay
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Natera | $390.86 | +5.45% | $53.08B | — | — | 19.6 | +37.7% |
| Myriad Genetics | $3.99 | −0.50% | $378.7M | — | — | 0.5 | −10.5% |
| Labcorp | $313.78 | −2.25% | $26.32B | 26.6 | 16.6 | 1.8 | +5.8% |
| Guardant Health | $178.12 | +2.44% | $23.33B | — | — | 19.7 | +44.3% |
| CareDx | $56.07 | +3.20% | $2.81B | 26.2 | 51.1 | 6.1 | +52.2% |
| Quest Diagnostics | $236.38 | −3.47% | $27.03B | 26.0 | 20.6 | 2.3 | +10.2% |
| Tempus AI | $77.42 | −0.79% | $13.67B | — | — | 9.5 | +21.6% |
| Abbott | $104.24 | +1.22% | $178.18B | 33.1 | 18.0 | 3.8 | +13.0% |
| NeoGenomics | $19.01 | −2.07% | $498.7M | — | 68.4 | 0.7 | +11.2% |
| Median | 26.4 | 20.6 | 3.1 | +12.1% |